Israeli biotech firm picks Indiana for North American headquarters
An Israeli agricultural biotechnology company will establish its North American headquarters in Indiana. It is the first to set up operations in the state through a $60 million initiative called Iron Nation-Indiana, which aims to bring Israeli technology firms to the U.S. market.IBI Ag, which develops biological crop protection products, will base U.S. field trials, regulatory work, partnerships and market-development activities in the state, Indiana Gov. Mike Braun said on Wednesday. The company’s decision is “a testament to our state’s dominance in the agricultural sector and our intentional and persistent pursuit of innovation,” Braun said.The company already works with Indiana-based Corteva Agriscience and plans additional collaborations with research institutions and agricultural organizations in the state.The announcement coincided with the Indiana–Israel BioHeartland Summit, which brings together Israeli and Indiana companies.Get the latest updates in our WhatsApp group.
Israeli agricultural biotechnology company IBI Ag will establish its North American headquarters in Indiana, marking the first company to do so through the $60 million Iron Nation-Indiana initiative, which aims to attract Israeli technology firms to the U.S. market. IBI Ag, which develops biological crop protection products, will conduct U.S. field trials, regulatory work, and market development from its new Indiana base. Indiana Governor Mike Braun stated that the decision is "a testament to our state's dominance in the agricultural sector and our intentional and persistent pursuit of innovation." The company already collaborates with Indiana-based Corteva Agriscience and plans further partnerships with local research institutions. This announcement was made during the Indiana–Israel BioHeartland Summit.
© All rights to the original article belong to the source. Din Online shows a headline, an excerpt and a link only. The objectivity rating is computed automatically and is an estimate only.
Discussion
No comments yet — be the first to comment.